CL2018001911A1 - Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano - Google Patents

Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Info

Publication number
CL2018001911A1
CL2018001911A1 CL2018001911A CL2018001911A CL2018001911A1 CL 2018001911 A1 CL2018001911 A1 CL 2018001911A1 CL 2018001911 A CL2018001911 A CL 2018001911A CL 2018001911 A CL2018001911 A CL 2018001911A CL 2018001911 A1 CL2018001911 A1 CL 2018001911A1
Authority
CL
Chile
Prior art keywords
diaza
oxo
amino
carboxyethyl
spiro
Prior art date
Application number
CL2018001911A
Other languages
English (en)
Inventor
Ingo Konetzki
Sven Kühnert
Achim Kless
Anita Wegert
Paul Ratcliffe
Ruth Jostock
Thomas Koch
Klaus Linz
Wolfgang Schröder
René Michael Koenigs
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of CL2018001911A1 publication Critical patent/CL2018001911A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Abstract

DERIVADOS DE 3-((HETERO)ARIL)-8-AMINO-2-OXO-1,3-DIAZA-ESPIRO-[4.5]-DECANO, SU PREPARACIÓN Y SU USO EN MEDICAMENTOS, EN PARTICULAR EN EL TRATAMIENTO DEL DOLOR.
CL2018001911A 2016-01-13 2018-07-13 Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano CL2018001911A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16151012 2016-01-13

Publications (1)

Publication Number Publication Date
CL2018001911A1 true CL2018001911A1 (es) 2018-10-19

Family

ID=55129633

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001911A CL2018001911A1 (es) 2016-01-13 2018-07-13 Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano

Country Status (30)

Country Link
US (7) US20170197970A1 (es)
EP (2) EP3402781B1 (es)
JP (2) JP6893516B2 (es)
KR (1) KR20180097732A (es)
CN (2) CN114149413A (es)
AR (2) AR107434A1 (es)
AU (1) AU2017206908B2 (es)
BR (1) BR112018014305B1 (es)
CA (1) CA3011176C (es)
CL (1) CL2018001911A1 (es)
CO (1) CO2018008447A2 (es)
CY (1) CY1122923T1 (es)
DK (1) DK3402781T5 (es)
EA (2) EA037598B1 (es)
EC (1) ECSP18060834A (es)
ES (1) ES2807549T3 (es)
HR (1) HRP20200782T1 (es)
HU (1) HUE049771T2 (es)
IL (2) IL260496B (es)
LT (1) LT3402781T (es)
MX (1) MX2018008643A (es)
NZ (1) NZ745185A (es)
PE (1) PE20221732A1 (es)
PL (1) PL3402781T3 (es)
PT (1) PT3402781T (es)
RS (1) RS60307B1 (es)
SI (1) SI3402781T1 (es)
TW (1) TWI635082B (es)
WO (1) WO2017121647A1 (es)
ZA (1) ZA201805356B (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793556B2 (en) 2016-01-13 2020-10-06 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807989B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807988B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10829480B2 (en) 2016-01-13 2020-11-10 Gruenenthal Gmbh 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
KR100729242B1 (ko) 2001-04-18 2007-06-15 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
DE60330456D1 (de) 2002-07-05 2010-01-21 Targacept Inc N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1628978A2 (en) 2003-05-23 2006-03-01 Zealand Pharma A/S Triaza-spiro compounds as nociceptin analogues and uses thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2666489C (en) 2006-10-19 2012-10-02 F. Hoffmann-La Roche Ag Imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors for diabetes
JP2010517964A (ja) * 2007-02-01 2010-05-27 グラクソ グループ リミテッド ＧｌｙＴ１トランスポーター阻害薬および神経学的および神経精神病学的障害の治療におけるその使用
WO2008124209A1 (en) 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
CN102046595B (zh) 2008-03-27 2014-03-05 格吕伦塔尔有限公司 取代的4-氨基环己烷衍生物
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
EP3154971A4 (en) 2014-06-13 2017-11-01 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
RS60223B1 (sr) 2016-01-13 2020-06-30 Gruenenthal Gmbh Derivati 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
EP3402784B1 (en) 2016-01-13 2020-03-11 Grünenthal GmbH 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
KR102417487B1 (ko) 2016-01-13 2022-07-06 노보 노르디스크 에이/에스 지방산 치환기를 가진 egf(a) 유사체
EA037598B1 (ru) 2016-01-13 2021-04-20 Грюненталь Гмбх Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана
AR107354A1 (es) 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
CA3011180A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2017121650A1 (en) 2016-01-13 2017-07-20 Grünenthal GmbH 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793556B2 (en) 2016-01-13 2020-10-06 Gruenenthal Gmbh 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807989B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10807988B2 (en) 2016-01-13 2020-10-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
US10829480B2 (en) 2016-01-13 2020-11-10 Gruenenthal Gmbh 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-l,3-diaza-spiro-[4.5]-decane derivatives

Also Published As

Publication number Publication date
AR107434A1 (es) 2018-05-02
HRP20200782T1 (hr) 2020-08-21
EP3402781B1 (en) 2020-03-04
AU2017206908B2 (en) 2020-07-09
CN114149413A (zh) 2022-03-08
AU2017206908A1 (en) 2018-08-30
LT3402781T (lt) 2020-06-10
ES2807549T3 (es) 2021-02-23
WO2017121647A1 (en) 2017-07-20
US20210188860A1 (en) 2021-06-24
IL285355A (en) 2021-09-30
PL3402781T3 (pl) 2020-09-21
JP7148660B2 (ja) 2022-10-05
ZA201805356B (en) 2021-04-28
BR112018014305A2 (pt) 2018-12-11
SI3402781T1 (sl) 2020-10-30
KR20180097732A (ko) 2018-08-31
BR112018014305B1 (pt) 2023-10-17
EP3722284A1 (en) 2020-10-14
JP2019501937A (ja) 2019-01-24
US20210032256A1 (en) 2021-02-04
RS60307B1 (sr) 2020-07-31
PT3402781T (pt) 2020-07-07
AR124672A2 (es) 2023-04-19
JP2021091716A (ja) 2021-06-17
EA201891611A1 (ru) 2019-01-31
US20230303573A1 (en) 2023-09-28
HUE049771T2 (hu) 2020-10-28
CA3011176C (en) 2023-09-19
US20190106429A1 (en) 2019-04-11
EA202190281A1 (ru) 2021-09-01
US20170197970A1 (en) 2017-07-13
CN108699006A (zh) 2018-10-23
ECSP18060834A (es) 2018-08-31
DK3402781T3 (da) 2020-05-18
CY1122923T1 (el) 2021-10-29
TW201730156A (zh) 2017-09-01
EP3402781A1 (en) 2018-11-21
US20190375754A1 (en) 2019-12-12
EA037598B1 (ru) 2021-04-20
US10807988B2 (en) 2020-10-20
US20180201616A1 (en) 2018-07-19
IL260496B (en) 2021-09-30
JP6893516B2 (ja) 2021-06-23
MX2018008643A (es) 2018-11-19
IL285355B1 (en) 2023-01-01
IL285355B2 (en) 2023-05-01
PE20221732A1 (es) 2022-11-07
CA3011176A1 (en) 2017-07-20
CN108699006B (zh) 2021-11-05
NZ745185A (en) 2024-03-22
TWI635082B (zh) 2018-09-11
CO2018008447A2 (es) 2018-08-31
DK3402781T5 (da) 2020-06-02

Similar Documents

Publication Publication Date Title
CO2018008444A2 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001910A1 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001909A1 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
MX2020003661A (es) Formas de dosificacion de liquidos, metodos de fabricacion y uso.
CL2015002897A1 (es) Inhibidores de bace1
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2015002835A1 (es) Nuevos derivados de piridina
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
CO2018008626A2 (es) Formulaciones de oritavancina
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
EA201700254A1 (ru) Комбинация
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
UA115417U (xx) Спосіб профілактики та лікування гіпоксичних змін при карбоперитонеумі
CL2016000822A1 (es) Tratamiento del cáncer con una combinación de plinabulina y taxano
UA113284U (uk) Спосіб лікування хворих на хронічний тонзиліт у поєднанні з атопічним дерматитом
BR112016026346A2 (pt) Derivados de pirrolidina-2,5-diona e seu uso, composições farmacêuticas e medicamento
UA94512U (uk) Лікувально-профілактичний засіб імуномодулюючої дії